Drug Company Touts Anti-Inflammatory Drug’s Role In Shortening COVID Recovery – Kaiser Health News

Eli Lilly said it planned to discuss with regulators the possible emergency use of baricitinib for hospitalized patients. Other news is about early research on an antibody that might neutralize COVID and how the virus controls the brain, as well.

AP:Anti-Inflammatory Drug May Shorten COVID-19 Recovery TimeA drug company says that adding an anti-inflammatory medicine to a drug already widely used for hospitalized COVID-19 patients shortens their time to recovery by an additional day. Eli Lilly announced the results Monday from a 1,000-person study sponsored by the U.S. National Institute of Allergy and Infectious Diseases. The study tested baricitinib, a pill that Indianapolis-based Lilly already sells as Olumiant to treat rheumatoid arthritis. (Marchione, 9/14)

The Hill:Drugmaker Says Anti-Inflamatory Medicine May Shorten COVID-19 Recovery TimeThe use of Baricitinib, arheumatoidarthritis drug from Eli Lilly, led to a one-day reduction in recovery time for patients when combined with Remdesivir compared to patients who only took Remdesivir, according to a trial. The finding was statistically significant, Eli Lilly said in a statement. The company did not release the full results of the study but stated the National Institute of Allergy and Infectious Diseases (NIAID) is expected to publish full results in peer-review studies and that additional analyses are ongoing to understand clinical outcome data, including safety and morbidity data. (9/14)

In other scientific developments

Fox News:University Of Pittsburgh Scientists Discover Antibody That 'neutralizes' Virus That Causes CoronavirusScientists at the University of Pittsburgh School of Medicine have isolated the smallest biological molecule that completely and specifically neutralizes SARS-CoV-2, the virus that causes the novel coronavirus. The antibody component is 10 times smaller than a full-sized antibody, and has been used to create the drug Ab8, shared in the report published by the researchers in the journal Cell on Monday. The drug is seen as a potential preventative against SARS-CoV-2. (Deabler, 9/14)

Fox News:Coronavirus Can 'Hijack' Brain Cells To Replicate Itself, Yale Researchers DiscoverThe coronavirus can affect the brain and hijack brain cells to replicate itself, Yale University researchers have discovered. A new study from Yale University, on BioRXiv, which is awaiting peer review, found that the brain is another organ susceptible to an attack by the novel coronavirus. (McGorry, 9/14)

Stat:23andMe Research Finds Possible Link Between Blood Type And Covid-19A forthcoming study from genetic testing giant 23andMe shows that a persons genetic code could be connected to how likely they are to catch Covid-19 and how severely they could experience the disease if they catch it. Its an important confirmation of earlier work on the subject. People whose blood group is O seemed to test positive for Covid-19 less often than expected when compared to people with any other blood group, according to 23andMes data; people who tested positive and had a specific variant of another gene also seemed to be more likely to have serious respiratory symptoms. (Sheridan, 9/14)

Read the rest here:
Drug Company Touts Anti-Inflammatory Drug's Role In Shortening COVID Recovery - Kaiser Health News

Commission urges international cooperation, continuing research in gene editing report – BioWorld Online

LONDON The international commission convened in the aftermath of Chinese scientist He Jiankuis shock announcement of the birth of gene edited twins has set a possible course to approval of heritable gene editing, but said the technique is far from ready for use.

At this time, it is not possible to specify how to move from research to clinical application because it is not possible to make precise edits, or avoid introducing off-target effects, the committee said.

No clinical use should be considered until it is clear it can be done precisely. There are a lot of gaps at the moment, said Kay Davies, commission co-chair and professor of genetics at Oxford University, speaking at the launch of the report.

Should they ever be used, it is vitally important that these technologies are used for medically justified interventions based on rigorous understanding of how the pathogenic variant leads to disease, Davies said.

If and when heritable human genome editing is proved reliable, initial applications should be limited to the prevention of serious monogenic diseases, such as cystic fibrosis, thalassemia, sickle cell anemia and Tay-Sachs disease, but only in cases where even with in vitro fertilization and preimplantation screening of embryos, couples would have no chance of having a biologically related child that was not affected by the condition.

As the report notes, instances where both prospective parents are homozygous for a disease gene are very rare. Even for a dominant disorder that can be inherited from a single defective gene, it would be rare for one parent to be homozygous. Commission member Michele Ramsay, of the University of the Witwatersrand, South Africa, said fewer than 20 families worldwide are likely to meet the criteria.

Thats why we need international cooperation, so it is transparent and open, and data can be pooled, Ramsay said. No floodgates are going to be opened for the initial uses we recommend.

The International Commission on the Clinical Use of Human Germline Gene Editing, set up by the U.K. Royal Society and the U.S. National Academies of Science and of Medicine, involves 18 expert members from 10 countries. They spent a year reviewing the scientific literature on CRISPR and other gene editing tools, consulting peer and patients groups and meeting the public.

For the prevention of serious monogenic disease, the commission has defined a responsible clinical translation pathway, from rigorous preclinical research that determines whether and how editing can be performed efficiently and with high accuracy, to clinical application, said Richard Lifton, co-chair of the commission and president of Rockefeller University.

Key technical barriers are assessing if an edit will be corrective and demonstrating the intended edit is present in all cells. These criteria for safe and effective use have not been met yet, said commission member Haoyi Wang, of the Chinese Academy of Sciences. The report sets out the progress of research needed to show editing is effective, and [can be done] with high specificity and accurate on target charges, without causing off-target effects or mosaicism, Wang said.

No one should be attempting to follow Hes example as things stand, the commission said. All countries in which human gene editing is being researched should put in place regulation to oversee progress toward potential clinical uses, and to prevent and sanction unapproved use.

There is great concern about the potential for rogue scientists embarking on heritable gene editing on their own, Lifton said. Ultimately, regulation will be at the countrywide level, but weve got to ensure the conditions are met to ensure proper regulatory oversight. There must be a mechanism for case by case evaluation and staged rollout of the technology, he said.

More research needed

To back those national regulations, an international science advisory panel should be established to continuously follow progress, assess if preclinical requirements have been met, review data on clinical outcomes from any regulated uses of human germline editing, and advise on risks and benefits of other potential applications.

More research is needed into the technology of genome editing in human embryos, to ensure that precise changes can be made without undesired off-target effects, said Davies. International cooperation and open discussion of all aspects of genome editing will be essential.

In addition to a scientific panel to follow the science, the commission also calls for a hotline to be set up, through which researchers could raise concerns about any inappropriate use of germline editing. I would emphasize the importance of a whistleblowing mechanism, said Davies. It is suggested this could be modeled on the World Anti-Doping Agency, which polices the use of prohibited substances in sports.

The commission stresses that it was solely concerned with assessing the science and defining the specific criteria and standards required before clinical use of germline editing is considered.

A separate committee set up by the World Health Organization and co-chaired by Margaret Hamburg, former head of the U.S. FDA, is looking at ethical issues and developing governance mechanisms for both heritable and somatic gene editing. The WHO committee is expected to publish its guidance later this year.

In December 2019, He was sentenced to three years in prison and fined $430,000 for illegally carrying out the human gene editing that led to the birth of the twin girls and of another baby, with heritable changes to their genomes.

As to how far in the future approval for germline gene editing might be, Wang said the technology is moving fast. Its a bit difficult to predict, but Im quite optimistic it will become more precise. Advances also will be needed in single cell genome sequencing to ensure there are no off-target effects, he said.

Read this article:
Commission urges international cooperation, continuing research in gene editing report - BioWorld Online

People with Heroin Addiction Have Unique Molecular Alterations to The Brain That Resemble Brain Disturbances Seen in Neurodegenerative Disorders Like…

MEDIA ADVISORY

FOR IMMEDIATE RELEASE: Nature Communications: Published Monday, September 14, 2020

Newswise Corresponding Author:Yasmin Hurd, PhD, Director of The Addiction Institute of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, and other coauthors.

Bottom Line:Herion-addicted individuals have alterations in the expression a gene called FYN - a gene known to regulate the production of Tau, a protein that is highly elevated and implicated in neurocognitive disorders like Alzheimers disease. The study emphasizes that opioid use can affect the brain in a way that might increase vulnerability of neural systems that trigger neurodegeneration later in life; however, since these changes are epigenetic (alterations in gene function that are influenced by environmental factors and not alterations of the DNA itself), they are reversible and medications that have already been developed to target FYN for neurodegenerative disorders may be studied as a novel treatment for opioid addiction.

Results:Interestingly, findings were consistent across human, animal and cell models. Through post-mortem analysis of the brains of human heroin users, the team found that, specifically in neurons, the most significantly impaired epigenetic region is related to a gene called FYN. Essentially, heroin opened up the DNA at the FYN gene, which encodes a protein called tyrosine kinase FYN, that is strongly linked to synaptic plasticity and which directly results in production of Tau. Too much Tau in the brain is associated with neurodegenerative diseases. They observed that expression and activity of tyrosine kinase FYN was also induced in rats trained to self-administer heroin and also in primary striatal neurons treated with chronic morphine in vitro. Additionally, they demonstrated that inhibition of the FYN kinase (either via pharmacological means or through genetic manipulation) reduces heroin-seeking and heroin-taking behaviors.

Why the Research Is Interesting:The findings will increase awareness about the potential impact of heroin to alter neural systems related to neurodegenerative disorders. The findings also identify FYN inhibitors as a novel therapeutic treatment for heroin use disorders.

Who: Human brains from a cohort of subjects who succumbed to heroin overdose and normal controls, translational animal model of rats trained to self-administer heroin, and primary striatal neurons treated with chronic morphine in vitro.

When: Adult animals were exposed to heroin and their brains studied.

What:They performed unbiased, cell-type-specific, genome-wide profiling of chromatin accessibility, providing insights into epigenetic regulation directly in the brains of heroin-addicted individuals. To assess the causal relationship between heroin use and FYN pathology, they studied the brains of rats trained to self-administer heroin and they hit primary striatal neurons with chronic morphine in petri dishes to examine the effect at the individual cellular level.

Study Conclusions:By scanning the entire genome of heroin users to identify whether disturbances in how genes are turned on or off exist, Mount Sinai researchers found that heroin opened up the DNA at the FYN gene. The FYN gene is known to regulate the production of Tau, a protein implicated in neurodegenerative disorder like Alzheimers disease, meaning that heroin may put users at an increased risk of neurodegenerative disease later in life. Importantly, these novel findings suggest that FYN inhibitors (which have already been developed and are being assessed for use in Alzheimers disease) may be promising therapeutic tools for heroin-use disorder.

Paper Title: Chromatin accessibility mapping of the striatum identifies tyrosine kinase FYN as a therapeutic target for heroin use disorder

Said Mount Sinai's Dr. Yasmin Hurd of the research: Drug overdoses due to opioid abuse remain at epidemic levels and continue to rise precipitously during the current pandemic, with novel treatments desperately needed. Direct molecular insights into the heroin-addicted human brain are critical to guide future therapies. Our new study findings clearly open up new lines of treatment opportunities for opioid use disorder, which could benefit and potentially save the lives of so many.

###

Read the original:
People with Heroin Addiction Have Unique Molecular Alterations to The Brain That Resemble Brain Disturbances Seen in Neurodegenerative Disorders Like...

New molecular therapeutics center established at MIT’s McGovern Institute – MIT News

More than 1 million Americans are diagnosed with a chronic brain disorder each year, yet effective treatments for most complex brain disorders are inadequate or even nonexistent.

A major new research effort at the McGovern Institute for Brain Research at MIT aims to change how we treat brain disorders by developing innovative molecular tools that precisely target dysfunctional genetic, molecular, and circuit pathways.

The K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience was established at MIT through a $28 million gift from philanthropist Lisa Yang and MIT alumnus Hock Tan 75. Yang is a former investment banker who has devoted much of her time to advocacy for individuals with disabilities and autism spectrum disorders. Tan is president and CEO of Broadcom, a global technology infrastructure company.This latest gift brings Yang and Tans total philanthropy to MIT to more than $72 million.

In the best MIT spirit, Lisa and Hock have always focused their generosity on insights that lead to real impact," says MIT President L. Rafael Reif. Scientifically, we stand at a moment when the tools and insights to make progress against major brain disorders are finally within reach. By accelerating the development of promising treatments, the new center opens the door to a hopeful new future for all those who suffer from these disorders and those who love them. I am deeply grateful to Lisa and Hock for making MIT the home of this pivotal research.

Engineering with precision

Research at the K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience will initially focus on three major lines of investigation: genetic engineering using CRISPR tools, delivery of genetic and molecular cargo across the blood-brain barrier, and the translation of basic research into the clinical setting. The center will serve as a hub for researchers with backgrounds ranging from biological engineering and genetics to computer science and medicine.

Developing the next generation of molecular therapeutics demands collaboration among researchers with diverse backgrounds, says Robert Desimone, McGovern Institute director and the Doris and Don Berkey Professor of Neuroscience at MIT. I am confident that the multidisciplinary expertise convened by this center will revolutionize how we improve our health and fight disease in the coming decade. Although our initial focus will be on the brain and its relationship to the body, many of the new therapies could have other health applications.

There are an estimated 19,000 to 22,000 genes in the human genome and a third of those genes are active in the brain the highest proportion of genes expressed in any part of the body. Variations in genetic code have been linked to many complex brain disorders, including depression, Parkinsons, and autism. Emerging genetic technologies, such as the CRISPR gene editing platform pioneered by McGovern Investigator Feng Zhang, hold great potential in both targeting and fixing these errant genes. But the safe and effective delivery of this genetic cargo to the brain remains a challenge.

Researchers within the new Yang-Tan Center will improve and fine-tune CRISPR gene therapies and develop innovative ways of delivering gene therapy cargo into the brain and other organs. In addition, the center will leverage newly developed single-cell analysis technologies that are revealing cellular targets for modulating brain functions with unprecedented precision, opening the door for noninvasive neuromodulation as well as the development of medicines. The center will also focus on developing novel engineering approaches to delivering small molecules and proteins from the bloodstream into the brain. Desimone will direct the center and some of the initial research initiatives will be led by associate professor of materials science and engineering Polina Anikeeva; Ed Boyden, the Y. Eva Tan Professor in Neurotechnology at MIT; Guoping Feng, the James W. (1963) and Patricia T. Poitras Professor of Brain and Cognitive Sciences at MIT; and Feng Zhang, James and Patricia Poitras Professor of Neuroscience at MIT.

Building a research hub

My goal in creating this center is to cement the Cambridge and Boston region as the global epicenter of next-generation therapeutics research. The novel ideas I have seen undertaken at MITs McGovern Institute and Broad Institute of MIT and Harvard leave no doubt in my mind that major therapeutic breakthroughs for mental illness, neurodegenerative disease, autism, and epilepsy are just around the corner, says Yang.

Center funding will also be earmarked to create the Y. Eva Tan Fellows program, named for Tan and Yangs daughter Eva, which will support fellowships for young neuroscientists and engineers eager to design revolutionary treatments for human diseases.

We want to build a strong pipeline for tomorrows scientists and neuroengineers, explains Hock Tan. We depend on the next generation of bright young minds to help improve the lives of people suffering from chronic illnesses, and I can think of no better place to provide the very best education and training than MIT.

The molecular therapeutics center is the second research center established by Yang and Tan at MIT. In 2017, they launched the Hock E. Tan and K. Lisa Yang Center for Autism Research, and, two years later, they created a sister center at Harvard Medical School, with the unique strengths of each institution converging toward a shared goal: understanding the basic biology of autism and how genetic and environmental influences converge to give rise to the condition, then translating those insights into novel treatment approaches.

All tools developed at the molecular therapeutics center will be shared globally with academic and clinical researchers with the goal of bringing one or more novel molecular tools to human clinical trials by 2025.

We are hopeful that our centers, located in the heart of the Cambridge-Boston biotech ecosystem, will spur further innovation and fuel critical new insights to our understanding of health and disease, says Yang.

The rest is here:
New molecular therapeutics center established at MIT's McGovern Institute - MIT News

Muscular Dystrophy Condition in Mice Reversed by RNA-Targeting Cas9 – Genetic Engineering & Biotechnology News

Myotonic dystrophy type I (DM1) is the most common type of adult-onset muscular dystrophy. DM1 is caused by mutations in the DMPK gene. A normal DMPK gene has 3 to 37 repetitions of the CTG sequence, while in DM1, there are hundreds to thousands of repetitions of this sequence. When a DMPK gene with too many CTG repeats is transcribed, the resulting RNA is too long. This abnormally long RNA is toxic to cells, and those affected experience progressive muscle wasting and weakness.

CRISPR-Cas9 is a technique increasingly used in efforts to correct the genetic defects that cause a variety of diseases. Now a research team from the University of California, San Diego (UCSD), School of Medicine, reports they redirected the technique to modify RNA in a method they call RNA-targeting Cas9 (RCas9), to eliminate the toxic RNA and almost fully reverse symptoms in a mouse model of myotonic dystrophy.

Their findings, The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy type 1, was published in Nature Biomedical Engineering and led by Gene Yeo, PhD, professor of cellular and molecular medicine at UCSD School of Medicine.

Myotonic dystrophy is part of a group of inherited disorders called muscular dystrophies. There are two major types of myotonic dystrophy: type 1 and type 2. The muscle weakness associated with type 1 particularly affects muscles farthest from the center of the body, such as those of the lower legs, hands, neck, and face. Muscle weakness in type 2 primarily involves muscles close to the center of the body, such as those of the neck, shoulders, elbows, and hips. The two types of myotonic dystrophy are caused by mutations in different genes.

Many other severe neuromuscular diseases, such as Huntingtons and ALS, are also caused by similar RNA buildup, explained Yeo. There are no cures for these diseases. Yeo led the study with collaborators at Locanabio and the University of Florida.

CRISPR-Cas9 works by directing Cas9 to cut a specific target gene, allowing researchers to inactivate or replace the gene. However, the Cas9 in the RCas9 method is guided to an RNA molecule instead of DNA. In a previous study, Yeo and his team established RCas9 as a means to track RNA in living cells in a programmable manner without genetically encoded tags. In a 2017 study, in lab models and patient-derived cells, the researchers used RCas9 to eliminate 95% of the abnormal RNA linked to myotonic dystrophy type 1 and type 2, one type of ALS and Huntingtons disease.

In the current study, the method goes further, by reversing myotonic dystrophy type 1 in a mouse model of the disease. Toxic RNAs expressed from such repetitive sequences can be eliminated using CRISPR-mediated RNA targeting, yet evidence of its in vivo efficacy and durability is lacking, noted the researchers. Here, using adult and neonatal mouse models of DM1, we show that intramuscular or systemic injections of adeno-associated virus (AAV) vectors encoding nuclease-dead Cas9 and a single-guide RNA targeting CUG repeats results in the expression of the RNA-targeting Cas9 for up to three months, redistribution of the RNA-splicing protein muscleblind-like splicing regulator 1, elimination of foci of toxic RNA, reversal of splicing biomarkers and amelioration of myotonia.

The researchers packaged RCas9 in a non-infectious virus. They then gave the mice a single dose of the therapy or a placebo. RCas9 reduced the abnormal RNA repeats by more than 50%, varying a bit depending on the tissue, and the treated myotonic dystrophy mice became indistinguishable from healthy mice.

To prevent the potential of the RCas9 proteins, developing an immune reaction in the mice, the researchers tried suppressing the mices immune systems briefly during treatment. As a result, they were surprised to see that they successfully prevented immune reaction and clearance. The researchers did not see signs of muscle damage, but found an increase in the activity of genes involved in new muscle formation.

Yeo believes the findings will open a new avenue of understanding and lead the way for treating other genetic diseases. This opens up the floodgates to start testing RNA-targeting CRISPR-Cas9 as a potential approach to treat other human genetic diseasesthere are at least 20 caused by buildup of repetitive RNAs, Yeo added.

Go here to read the rest:
Muscular Dystrophy Condition in Mice Reversed by RNA-Targeting Cas9 - Genetic Engineering & Biotechnology News

Global CRISPR And CRISPR-Associated Genes Market Report Provide Insights into Growth strategic Adopted by Top Companies || Thermo Fisher Scientific,…

The foremost aim of this report titled Global CRISPR And CRISPR-Associated Genes Market isto provide valuable understandings into CRISPR And CRISPR-Associated Genes market to the industry participants including company accounts, industry investors, and industry members to facilitate them to adopt correct strategic decisions regarding the opportunities in the global CRISPR And CRISPR-Associated Genes market.

Global CRISPR And CRISPR-Associated Genes Market 2020 offers important intel about the Worldwide CRISPR And CRISPR-Associated Genes market along with the market size, share, and estimates for the period between 2020 and 2025.

Request For The Free Sample Copy Of CRISPR And CRISPR-Associated Genes Market Report Which Provides ( Key Market Trends | Growth Forecast | Sale | Revenue | Manufactures ) @https://www.eonmarketresearch.com/sample/43610

Also, the report unleashes opportunities for newcomers driving them towards tremendous growth in the global CRISPR And CRISPR-Associated Genes market. The quantitative information presented in this report is based on the rigorous primary research as well as extensive secondary research. This data is then analyzed by our international team of analysts who are specialists belonging to the CRISPR And CRISPR-Associated Genes market and developed strategic intel to provide the latest information on the global CRISPR And CRISPR-Associated Genes market. In addition to that, all segments are analyzed separately in the context of this report, which offers key growth pockets within CRISPR And CRISPR-Associated Genes market circumstances.

This report examines the global CRISPR And CRISPR-Associated Genes market based on product type, application service, client, and geography. The global CRISPR And CRISPR-Associated Genes market covers major geographies and leading economies in each of these geographies.

Note: Our Free Sample Report Offers a Short Outline of the Report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology

Buy This Premium Report: https://www.eonmarketresearch.com/buy/43610

Table of Contents

1. Executive Description2. Assumption and Acronyms Used3. Methodology of analysis4. Description of the industry5. International business research and forecasting, by form6. Global Market Research and Forecast, Applications7. Global Market Outlook and Forecast, Regions8. North American Industry Review and Prediction9. Latin American Business Review and Forecast10. European Business Review and Prediction11. Asian Pacific Industry Review and Prediction12. The Middle East and Africa Business Review and Forecast13. Landscape Competition

Do Inquiry Before Purchasing Report Here and Ask For Discount Here- https://www.eonmarketresearch.com/enquiry/43610

To summarize this, the CRISPR And CRISPR-Associated Genes market report discloses major discoveries in the and conclusions about this industry. Similarly, the report reveals different CRISPR And CRISPR-Associated Genes information about various aspects including but not limited to, traders/distributors, suppliers, manufacturers, sales channel, and appendix. In a word, the complete CRISPR And CRISPR-Associated Genes report adds up to the insights available at the hands of industry participants in the CRISPR And CRISPR-Associated Genes market.

***Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like United States, Europe, Middle East, and Africa or Asia-Pacific.***

About Us:

Eon Market Research (EMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers.

Contact Us:

Eon Market ResearchPhone: +1 703 879 7090Email:[emailprotected]

The rest is here:
Global CRISPR And CRISPR-Associated Genes Market Report Provide Insights into Growth strategic Adopted by Top Companies || Thermo Fisher Scientific,...

Cardiff Oncology to Host Key Opinion Leader Call Discussing KRAS-Mutated Colorectal Cancer and Highlighting Data from Onvansertib Phase 1b/2 Trial -…

SAN DIEGO, Sept.15, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq:CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, today announced that it will host a key opinion leader (KOL) call focused on KRAS-mutated colorectal cancer and highlighting data from its onvansertib Phase 1b/2 clinical trial, on Wednesday, Sept. 23, 2020 from 11 a.m. 12:30 p.m. EDT.

On the call, Dr. Mark Erlander, Cardiff Oncology's chief executive officer, and Key Opinion Leaders Afsaneh Barzi, M.D., Ph.D. (City of Hope Comprehensive Cancer Center) and Heinz-Josef Lenz, M.D., FACP (USC Norris Comprehensive Cancer Center) will participate in a discussion featuring the latest data from Cardiff's Phase 1b/2 clinical trial evaluating onvansertib in combination with FOLFIRI and bevacizumab for the second line treatment of patients with KRAS-mutated metastatic colorectal cancer. Dr. Barzi will begin the discussion by providing an overview of the history of KRAS in clinical practice, the challenges of drug development and targeting of KRAS, and the value of KRAS as a biomarker for patient selection and predicting response to treatment. Dr. Lenz will follow with a presentation of the onvansertib clinical trial data featured at the European Society of Medical Oncology (ESMO) Virtual Conference 2020. A question and answer session will follow the formal presentations.

You may register for the call by clicking here.

About the KOLs

Afsaneh Barzi, M.D., Ph.D.is a practicing medical oncologist, associate clinical professor for gastrointestinal oncology, and clinical director of AccessHope at City of Hope Comprehensive Cancer Center. Prior to joining City of Hope, Dr. Barzi was an associate professor of clinical medicine at the Keck School of Medicine of the University of Southern California. She earned her M.D. from Tehran University of Medical Sciences, then went on to earn a Master's in Health Informatics and a Doctorate in Public Health Management and Policy Sciences from the University of Texas Health Science Center in Houston. Dr. Barzi completed a fellowship in hematology and oncology at the Cleveland Clinic's Taussig Cancer Center. Her research and practice are focused on gastrointestinal malignancies with an emphasis on colorectal cancers. Her unique perspective on patterns of care in patients with colorectal cancer arises from the combination of her expertise in real-world data and her experience with biomarker discovery and the use of biomarkers for personalized care.

Heinz-Josef Lenz, M.D., FACPis the associate director for clinical research and co-leader of the gastrointestinal (GI) cancers program at the University of Southern California Norris Comprehensive Cancer Center. Dr. Lenz is professor of medicine and preventive medicine, section head of gastrointestinal oncology in the division of medical oncology and co-director of the Colorectal Center at the Keck School of Medicine of the University of Southern California. Dr. Lenz received his medical degree from Johannes-Gutenberg Universitt in Mainz, Germany, in 1985. He completed a residency in hematology and oncology at the University Hospital Tbingen in Germany, a clerkship in oncology at George Washington University in Washington, DC, and a clerkship in hematology at Beth Israel Hospital of Harvard Medical School in Boston, Massachusetts. He served subsequent fellowships in biochemistry and molecular biology at the University of Southern California Norris Comprehensive Cancer Center. An active researcher, Dr. Lenz focuses on topics including the regulation of gene expression involved in drug resistance, patients at high risk of developing colorectal cancer, and determination of carcinogenesis, methods of early detection, and better surveillance of these cancers. He is a member of several professional societies, including the American Association for Cancer Research, the American Gastroenterology Association, and the National Society of Genetic Counselors. He also serves on the National Advisory Board of a number of professional organizations. Dr. Lenz is the author of numerous peer-reviewed publications and invited papers, reviews, and editorials. He also serves as co-chair of the GI Committee and Correlative Science Committee for SWOG. He is a member of the National Cancer Institute (NCI) Task Force for Gastroesophageal Cancer, the NCI Steering Committee, and the NCI Translational Science Committee.

About Cardiff Oncology, Inc.

Cardiff Oncology (formerly Trovagene, Inc.) is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment.We have three ongoing clinical programs that are demonstrating the safety and efficacy of onvansertib: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga (abiraterone)/prednisone in metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). For more information, please visit https://www.cardiffoncology.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, our need for additional financing; our ability to continue as a going concern; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; our ability to develop tests, kits and systems and the success of those products; regulatory, financial and business risks related to our international expansion and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2019, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Cardiff Oncology Contact:

Vicki KelemenChief Operating Officer858-952-7652[emailprotected]

Investor Contact:

Joyce AllaireLifeSci Advisors212-915-2569[emailprotected]

Media Contact:Karen O'Shea, Ph.D.LifeSci Communications929-469-3860[emailprotected]

SOURCE Cardiff Oncology, Inc.

Cardiff Oncology

Continued here:
Cardiff Oncology to Host Key Opinion Leader Call Discussing KRAS-Mutated Colorectal Cancer and Highlighting Data from Onvansertib Phase 1b/2 Trial -...

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas | More News | News…

DetailsCategory: More NewsPublished on Wednesday, 16 September 2020 10:43Hits: 105

NEW YORK, NY, USA I September 15, 2020 I As part of a two-day virtual Investor Day, Pfizer Inc. (NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Companys efforts to battle the COVID-19 pandemic on multiple fronts, including new data on the BNT162b2 vaccine candidate being developed in collaboration with BioNTech SE. The pipeline updates contribute to the Companys expectation of at least a 6% revenue CAGR over the next five years, as well as delivery of longer-term topline growth beyond that period.

Pfizers goal of delivering up to 25 breakthroughs to patients by the year 2025 has 38 such opportunities to draw from as of today, including the companys 20-valent pneumococcal conjugate vaccine candidate (20vPnC). On a non-risk adjusted basis, these opportunities collectively represent more than $15 billion (excluding 20vPnC) in potential incremental revenue for Pfizer from 2020 to 2025, as well as aggregate peak annual sales potential of $35 billion to $40 billion (including 20vPnC). If successful, the Companys COVID-19 programs would be incremental to these estimates.

Pfizers purpose Breakthroughs that change patients lives has never been more relevant, and our R&D pipeline has never been more dynamic, said Dr. Albert Bourla, Pfizer Chairman and CEO. I am proud of the truly transformational science that our research and clinical teams are bringing to the fight against disease, as well as the unprecedented speed with which we are advancing our clinical programs in the battle against COVID-19. In the coming months and years, I look forward to the new Pfizer continuing to demonstrate the agility and innovative spirit of a biotech combined with the scale of Big Pharma. With the depth and breadth of our current portfolio, the tremendous potential of our pipeline and scientific engine, and the power of our culture of innovation, we are poised to continue delivering meaningful value to patients by addressing some of the worlds most difficult health challenges.

UPDATES ON COVID-19 DEVELOPMENT PROGRAMS

Pfizer announced several key advances in its efforts to protect humankind from the COVID-19 pandemic and prepare the pharmaceutical industry to better respond to future global health crises.

BNT162 mRNA-based Vaccine Program

Pfizer and BioNTech shared several updates from their BNT162 mRNA-based vaccine program against SARS-CoV-2, the virus that causes COVID-19 disease, including:

Protease Inhibitor Program

The company announced the initiation of its Phase 1b clinical trial to evaluate the safety of a novel investigational therapeutic for COVID-19, PF-07304814. Of note,

THERAPEUTIC AREAS OF FOCUS

Pfizer shared significant research advances across its various therapeutic areas including candidates with blockbuster potential expected to launch by 2025.

Vaccines

In addition to the COVID-19 vaccine program, Pfizer aims to deliver five innovative vaccines by 2025, subject to clinical success and regulatory approval. Updates on these late-stage clinical development programs include:

Rare Disease

Pfizers Rare Disease late-stage pipeline currently includes three gene therapy programs that, if successful, are expected to gain regulatory approval by the end of 2023, with an additional pipeline of 10 preclinical initiatives that are at various stages of maturity. Key updates include:

Oncology

Pfizers Oncology pipeline has the potential to deliver up to 14 approvals expected by the end of 2025 and the potential for 24 new molecular entities in the clinic by the end of 2021. Key updates included, for the first time, early-stage opportunities obtained from the 2019 acquisition of Array BioPharma:

Inflammation and Immunology

The Inflammation & Immunology pipeline is focused on patients with autoimmune and chronic inflammatory diseases across rheumatology, gastroenterology and dermatology, with five distinct immuno-kinases, in oral and topical formulations, studied for potential treatment of 10 diseases, and three additional novel biologics in Phase 2 studies. Key updates included:

Internal Medicine

The Internal Medicine pipeline addresses the increasing global burden of cardiometabolic disease, with nine investigational medicines in active clinical studies and additional therapies in the pre-clinical pipeline. Key updates included:

To access a replay of the webcast, including audio, video and presentation slides, visit our web site at http://www.pfizer.com/investors.

About Pfizer: Breakthroughs That Change Patients Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at http://www.Pfizer.com. In addition, to learn more, please visit us on http://www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

SOURCE: Pfizer

Excerpt from:
Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas | More News | News...

Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer – GlobeNewswire

Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer

Experienced biotech executive to lead the next phase of growth

14 September 2020

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (Silence or the Company), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces the appointment of Mark Rothera as President and Chief Executive Officer (CEO) and Board member, effective immediately. Iain Ross, who has been Executive Chairman since December 2019, has today assumed his previous position of Non-Executive Chairman.

Mr. Rothera brings more than 30 years of experience in the biopharmaceutical industry, with a strong record of commercial and operational leadership, including driving the successful build of multiple biotech companies, predominantly in the field of rare or specialty diseases. Prior to joining Silence, Mr. Rothera served as CEO of Orchard Therapeutics (Orchard), where he oversaw its transformation from a small U.K.-based, privately held company with two clinical-stage programmes into a leading gene therapy company with seven clinical-stage programmes and fully integrated capabilities. Under his leadership, Orchard completed an initial public offering of American Depositary Shares on the Nasdaq Global Market and during his tenure that company secured more than $600 million in financing and grew from a market capitalization of $250 million to more than $1.7 billion at its peak.

Prior to Orchard, Mr. Rothera served as Chief Commercial Officer of PTC Therapeutics (PTC), where he helped transition that company from a privately held R&D biotechnology company to a publicly traded, commercial-stage company with a global footprint, including the successful launch of two rare disease therapies. He also previously served as Global President of Aegerion Pharmaceuticals Inc. and Vice President and General Manager of commercial operations at Shire Human Genetic Therapies for Europe, Middle East and Africa. Mr. Rothera received an M.A. in Natural Sciences from Cambridge University and an M.B.A. from the European Institute for Business Administration (INSEAD).

Based out of Silences New York City office, Mr. Rothera will lead the continued global expansion of the Company. His appointment follows the completion of Silences Nasdaq listing on 8 September 2020 and aligns with the strategy of increasing the Companys presence in the United States.

Iain Ross, Chairman of Silence Therapeutics plc, said: "On behalf of the Silence Board and the entire Silence team, I welcome Mark to the Company. Following a thorough search, Marks appointment reflects his proven leadership skills and strong track record in growing successful biotechnology companies and building shareholder value. I believe he will now provide the leadership necessary to grow Silence into a leading international biotechnology company built upon our innovative siRNA technology platform, proprietary product pipeline and validating industry partnerships.

On a personal note, and on behalf of the Board, I would like to thank the management team and staff at Silence for their support, hard work and tremendous resilience during the current COVID-19 pandemic and over the past nine months whilst I have been Executive Chairman. The Company has made great strides during this period, and is now in a strong position, both operationally and financially, and ready for Mark to take the helm.

Mark Rothera, President and CEO of Silence Therapeutics plc, added: It is an honour to take the role of leading Silence at this time in the Companys history. I believe the Company is poised to capitalise on its important siRNA technology platform, pipeline and research capabilities built over 18 years, and position itself as a leader in the RNAi field. The Company has made great strides under Iains leadership and I look forward to working with the Board, the management team and Silence employees to build upon this momentum.

Director disclosures

The following information is being disclosed pursuantto Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Mark Rothera

Full name and age: Mark Andrew Rothera (aged 58)

Current Directorships or Partnerships:Genpharm

Previous Directorships or Partnerships in the last 5 years:Orchard Therapeutics plcPTC Therapeutics International LimitedAlliance for Regenerative Medicine

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

Enquiries:

About Silence TherapeuticsSilence Therapeutics is developing a new generation of medicines by harnessing the bodys natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silences proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silences wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing SLN500 in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

The person who arranged for the release of this announcement on behalf of the Company was Rob Quinn, Chief Financial Officer.

Forward-Looking StatementsCertain statements made in this announcement are forward-looking statements, including with respect to the Companys clinical and commercial prospects. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Go here to see the original:
Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer - GlobeNewswire

Kim Dunbar Explains Nanotechnology Applications and Where Its Likely to Lead – Yahoo Finance

Kim Renee Dunbar Elaborates on Nanotechnology Applications and Where They Might lead

COLLEGE STATION, TX / ACCESSWIRE / September 15, 2020 / Kim Dunbar is a Distinguished Professor of Chemistry at Texas A & M University. She's won numerous awards for her work in inorganic chemistry. She currently focuses on coordination chemistry, which opens up many avenues to explore. She is one of the researchers leading the way in nanotechnology. She states that nanotech is currently used in various applications, which is expected to increase.

What is Nanotech?

Nanotech involves controlling matter at the molecular level. Kim Dunbar explains this gives scientists options that were once the stuff of science fiction. Nanotech spans all scientific disciplines, including chemistry, engineering, and materials science. Nanoparticles are measured in nanometers. There are 25,400,000 nanometers in an inch.

Kim Dunbar Explains Nanotech Today

Kim Dunbar states that nanotechnology is now commonly used in the medical field. Nano drugs are one exciting application. Nanotechnology allows drugs to be delivered to highly targeted areas. This can lead to more effective treatments with fewer side effects than traditional therapies. Nanoscience ts also targeted at increasing computing power and memory in electronic devices while scaling down the size. Nanotechnology has usage in batteries and solar power cells. It is also being used in surprising applications in food. According to Kim Renee Dunbar, clay nanoparticles are being used to prevent gases from entering food packaging.

The Future of Nanotech

When it comes to the future of nanotech, Kim Renee Dunbar says there are sure to be surprises. One interesting application is sensors for food. It is hypothesized that carbon nanotubes could be placed on food packaging to detect food spoilage. Nanosensors will also be able to detect bacteria in food packaging plants themselves. This could provide safety testing at a much quicker and cost-effective rate than lab testing.

Kim Dunbar says there are many medical applications on the horizon as well. One of these is nanotech sensors that are injected into the body. This would allow doctors to monitor the patient or check for conditions in a less invasive way. There is an almost endless amount of possibilities for uses of these "electroceuticals."

Story continues

Self-healing materials are another concept Kim Renee Dunbar finds fascinating. Nanoparticles could go where they were needed in the material to fill in cracks or worn areas. They could also be used as sensors to detect structural damage to bridges and nuclear power plants before the potential damage can pose a danger.

While these applications may sound like science fiction, Kim Renee Dunbar says they are closer than you think. It's hard to imagine the changes that nanotechnology will eventually bring about as research continues, but it's a safe bet that the world will benefit from these emerging technologies.

CONTACT:

Caroline Hunter

Web Presence, LLC

+1 7865519491

SOURCE: Kim Dunbar

View source version on accesswire.com: https://www.accesswire.com/606145/Kim-Dunbar-Explains-Nanotechnology-Applications-and-Where-Its-Likely-to-Lead

See the original post:
Kim Dunbar Explains Nanotechnology Applications and Where Its Likely to Lead - Yahoo Finance

2020-2021 NNI NanoEHS Webinars Will Begin in November 2020 – Lexology

According to the Summer 2020 edition of the National Nanotechnology Coordination Office (NNCO) Quarterly Newsletter, the 2020-2021 National Nanotechnology Initiative (NNI) nanomaterial environmental, health, and safety (nanoEHS) webinars will begin in November 2020. According to the Newsletter, the Nanotechnology Environmental and Health Implications (NEHI) Working Group is planning nanoEHS webinars to present progress in the following areas: nanomaterial measurement infrastructure; human exposure assessment; human health; environment; risk assessment and risk management methods; and informatics and modeling. The Newsletter notes that these are the research areas identified in the NNI Environmental, Health, and Safety Research Strategy (NNI EHS Research Strategy). The inaugural webinar will provide an overview of the research environment when the NNI EHS Research Strategy was developed, the major questions posed, and how collaborations and networks created a research infrastructure to address these questions. NNI will post more information at https://www.nano.gov/publicwebinars as it becomes available.

See the rest here:
2020-2021 NNI NanoEHS Webinars Will Begin in November 2020 - Lexology

Growth Opportunities for Emerging Insulation Materials, 2020: Enhancing Performance of Thermal Insulating Material Through Composite Technology and…

DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities for Emerging Insulation Materials" report has been added to ResearchAndMarkets.com's offering.

Growth Opportunities for Emerging Insulation Materials provides a review of both current and emerging innovations on insulation materials and their potential adoption as cost-efficient and high-performance materials within industries. The research service highlights the key factors that influence R&D and adoption efforts across various geographic regions. It also provides a list of noteworthy innovations and perspectives across the globe and highlights key innovators.

Insulation materials, either in fibrous, cellular or granular form, are adopted across industries such as building and construction, packaging, electronics, consumer goods, energy, manufacturing, oil & gas, aerospace, and automotive. Apart from being a thermal barrier, the materials function as anticorrosion, anti-flame, enhance the durability, and anti-microbial protection. The insulation system comes in the form of solids, liquids or gases, helping to enhance the quality as well as reduce the tendency of energy or heat loss of the insulated product.

However, most of the traditional insulation materials, such as fiberglass, mineral wools, polyurethane foam and aluminum foil have limitations either in the form of its mechanical properties whereby it tends to break or crack when being exposed to extreme surroundings or in its thermal or chemical properties where constant exposure to extreme surroundings reduces its effectiveness. These insulation materials have also contributed to health and environment issues, such inhalation during the application of fiberglass lead could lead to lung diseases as well as the release of chlorine atoms from the polyurethane foam which leads to the thinning of the ozone layer and global warming.

Stakeholders such as the University of California, US Uppsala University, Sweden, Japan Insulation, Japan, and Showa Denko Packaging Co. Ltd., Japan have introduced approaches to develop sustainable alternatives in insulation materials. Across industries, stakeholders, such as Knauf Insulation, US, IMT Mines Als, France, Showa Denko Packaging Co. Ltd., Japan, Terreal Malaysia Sdn Bhd, Malaysia have introduced technologies such as aerogel composites, bio-based composites, aluminum-polyester composites, and ceramic nanofiber and nanocellulose as sustainable alternatives for developing cost-efficient and high-performance insulation technology.

Key Topics Covered:

1.0 Executive Summary

1.1 Research Scope

1.2 Research Methodology

1.3 High Interest on Enhancing the Performance of Insulation Materials throughout the Regions

1.4 The Multi-functional Insulation Material Exists in three Different Structures

1.5 The Limitations and Opportunities of the Insulation Materials

1.6 Factors influencing the Continuous Growth of Insulation Materials

1.7 High Performance and Environmental Friendly Features Act as Key Factors for Material Adoption

2.0 Technology Overview

2.1 Insulation Material: Definitions

2.2 Fibrous Insulation is the most Mature Insulation Technology

2.3 Cellular Insulation Exists in both Solid and Liquid Insulation Structures

2.4 Granular Insulation has Opportunities for Developing Environmentally Friendly Insulation

2.5 Enabling High-performance Reflective Insulation through Composite Technology Development

2.6 Gas Insulation Has been Adopted for Enhancing other Types of Insulation Systems

3.0 Industry Assessment

3.1 Overview of Insulation Material Technology

3.2 Adoption of Aerogel Composite as Environmental Friendly Alternative of Insulation Technology in the Building and Construction Industry

3.3 Continuous Interest Within the European Regions on Aerogel and Nanotechnology as Emerging Insulation Technology in Built Environment

3.4 Certification for Insulation System Building and Construction Industries Across the North America and Europe Regions

3.5 Emerging Participants in Insulating Material in the Building and Construction Industry

3.6 Developing High Performance Insulation System from Recyclable Material

3.7 Increasing Interest in Developing High Performance Insulation System in the Automotive, Transportation, and Aerospace Industries

3.8 Emerging Participants in Insulating Material in the Automotive & Transportation, Aerospace & Defense Industries

3.9 Future Potential of Sustainable Alternative of Thermal Insulation

3.10 Enhancing the Performance of Insulation Technology in Electronics, Energy & Power System Industries Through Bio-based Composite

3.11 Emerging Participants in Innovations in Insulating Material the in Electronic, Energy & Power System Industries

3.12 The Future Potential of Lightweight, High Performance Insulation System

3.13 High Research Interest of Biocomposite in Insulation System for the Packaging Industry in the European Region

3.14 Emerging Participants in Insulating Material in Packaging

3.15 Future Adoption of Fibrous Insulation in the Packaging Industry

3.16 Gradual Interest in Adoption of Composite and Nanotechnology Alternative Within European Regions in the Manufacturing, Oil and Gas Industries

3.17 Emerging Participants in the Manufacturing, Oil and Gas Industries

3.18 The Adoption of Lightweight and Energy Saving Insulation System in the Manufacturing Industry

4.0 Innovations Indicators

4.1 Patent Activity on Insulation Materials During 2017 to 2019

4.2 High Interest on Research Studies in China

4.3 High Government Funding Across the Regions

4.4 High Interest in Product Development Across the Regions

4.5 High Interest in Technology Development in the Asia-Pacific Region

4.6 Continuous Efforts in Driving Circular Approach in Industries

5.0 Future Prospects for Emerging Insulation

5.1 Comparative Analysis of Emerging Insulation Materials in the Next Five Years

5.2 Comparative Analysis of Potential Insulation Materials in the Next Ten Years

5.3 Emerging Insulation Materials Production- Technology Comparative Analysis

6.0 Growth Opportunities for Insulation Materials

6.1 Future Potential in Developing Circular Economy Within the High Performance Insulation Materials

6.2 Strategic Imperatives: Critical Success Factors

6.3 Growth Opportunities: Enhancing Performance of Thermal Insulating Material Through Composite Technology and Nanotechnology

6.4 Increasing Number of Aerogel Composite Innovations and Nanotechnology Across the Regions

6.5 Gradual Interest for Bio-based Insulation System Across the Regions

6.6 High Interest in Adoption of Recycled Materials as Emerging Insulation Technology in European and Asia-Pacific Regions

7.0 Key Contacts

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/jmpq0s

See the original post:
Growth Opportunities for Emerging Insulation Materials, 2020: Enhancing Performance of Thermal Insulating Material Through Composite Technology and...

Global Organic Field-effect Transistor (OFET) Market Business Prospect and Industry Research Report 2025 || University of California, Santa Barbara,…

The Global Organic Field-effect Transistor (OFET) Market 2020 Research Report is a professional and detailed study about the current and forecast state With COVID 19 Impact Analysis of the market.

Eon Market Research offers a 360-degree view of the Global Organic Field-effect Transistor (OFET) Market and offers accurate forecasting and also covers competitive landscapes, with in-depth market segmentation including type segment, industry segment, channel segment, etc., vital trends and strategic recommendations to enable our clients. It also includes different clients data, which is very crucial for the manufacturers.

The historical information of the global Organic Field-effect Transistor (OFET) market and evaluate the present market scenario based on the key factors determining the trajectory of this Organic Field-effect Transistor (OFET) market with the help of primary and secondary data, the Organic Field-effect Transistor (OFET) market research report projects the future and makes a valid prediction. Moreover, the Organic Field-effect Transistor (OFET) industry research report also incorporates insightful information from industry specialists to uplift readers to make well-informed business decisions. The Organic Field-effect Transistor (OFET) market report also uses SWOT analysis and Porters five forces analysis to shed light on the important elements of the Organic Field-effect Transistor (OFET) Market.

Request Free Sample Report of Organic Field-effect Transistor (OFET) Market @ https://www.eonmarketresearch.com/sample/66153

(If you have any special requirements, please let us know and we will offer you the report as you want.)

** Note This report sample includes:

Major Players Are:

University of California, Santa Barbara, Catalan Institute of Nanoscience and Nanotechnology, Graphenea and Chalmers University of Technology, National Institute of Material Sciences And More

Market Segmentation:

By Type:

N type transistorP type transistor

By Applications:

Flexible OLED displaysSmart cardsTags

Buy This Premium Report @https://www.eonmarketresearch.com/buy/66153

Regions & Countries Mentioned In The Organic Field-effect Transistor (OFET) Market Report:

The report covers significant viewpoints:

Inquiry before Buying Organic Field-effect Transistor (OFET) Market 2020 Report and Ask For Discount Here @https://www.eonmarketresearch.com/enquiry/66153

Table of Content

About Us:

Eon Market Research (EMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers.

Contact Us:

Eon Market Research

Phone: +1 703 879 7090

Email: [emailprotected]

See the original post:
Global Organic Field-effect Transistor (OFET) Market Business Prospect and Industry Research Report 2025 || University of California, Santa Barbara,...

Nanotechnology in Cancer Treatment Market Covid-19 Impact on Industry, Size, Trends, and Forecast to 2025 by: Merck,Ferro, AMAG Pharmaceuticals,…

The following report offers a comprehensive and an in detail assessment of the Nanotechnology in Cancer Treatment market and focuses on the key growth contributors of the market to help the clients better understand the current scenario of the market while taking into account the history of the market over the past years as well as the future scope of growth and forecast that have also been discussed in depth in the following report. The report covers most of the global regions such as APAC, North America, South America, Europe, Middle East and Africa, hence ensuring a global and evenly distributed growth curve as the market matures over the time.

Top Market Players covered in this report are:Merck,Ferro, AMAG Pharmaceuticals, Capsulution Nanoscience, AstraZeneca, Affymetrix

The report takes into account the important factors and aspects that are crucial to the client to post good growth and establish themselves in the Nanotechnology in Cancer Treatment market. Some of these aspects are sales, revenue, market size, mergers and acquisitions, risks, demands, new trends and technologies and much more are taken into consideration to give a complete and detailed understanding of the market conditions.

Get Sample PDFBrochure@https://www.reportsintellect.com/sample-request/1244832?ata

Description:

This report has the updated data on the Nanotechnology in Cancer Treatment market and as the international markets have been changing very rapidly over the past few years the markets have gotten tougher to get a grasp of and hence the analysts here at Reports Intellect have prepared a detailed report while taking in consideration the history of the market and a very detailed forecast along with the market issues and their solution.

The given report focuses on the key aspects of the markets to ensure maximum benefit and growth potential for clients and our extensive analysis of the market will help the clients to achieve this much more efficiently. The report has been prepared by using primary as well as secondary analysis in accordance with porters five force analysis which has been a game-changer for many in the Nanotechnology in Cancer Treatment market. The research sources and tools used to assess the report are highly reliable and trustworthy.

Nanotechnology in Cancer Treatment Market Type Coverage:

Nanostructured MaterialsNanotoolsNanodevices

Nanotechnology in Cancer Treatment Market Application Coverage:

HospitalLaboratory

Market Segment by Regions and Nations included:

North America (United States, Canada, Mexico)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

Europe, Middle East and Africa (Germany, France, UK, Russia and Italy, Saudi Arabia, UAE, Egypt, Nigeria, South Africa)

Discount PDF Brochure @https://www.reportsintellect.com/discount-request/1244832?ata

Competitive Analysis:

The report offers effective guidelines and recommendations for players to secure a position of strength in the Nanotechnology in Cancer Treatment market. The newly arrived players in the market can up their growth potential by a great amount and also the current dominators of the market can keep up their dominance for a longer time by the use of this report.

The report includes the detailed description of mergers and acquisitions will help you to get a complete idea of the market competition and also give you extensive knowledge on how to excel ahead and grow in the market.

Reasons to buy:

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

sales@reportsintellect.comPhone No: + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,`Atlanta, GA 30303

See the article here:
Nanotechnology in Cancer Treatment Market Covid-19 Impact on Industry, Size, Trends, and Forecast to 2025 by: Merck,Ferro, AMAG Pharmaceuticals,...

Anatomy of a Goal: Mihailovic gives Fire an early lead vs. the Crew – Massive Report

Welcome back to the Anatomy of a Goal, where each week we dissect one goal (or near goal) from Columbus Crew SCs previous match.

For match 11 of the 2020 MLS Season, we take a look at Djordje Mihailovics 11th minute goal for Chicago Fire that gave the Fire a 1-0 lead against the Crew on Saturday.

Heres a look at the goal from Chicagos young attacker.

Columbus began Saturdays match against a brand-refreshed version of its old foes with a surprising lineup. Designated Player Lucas Zelarayan missed his second straight match with a slight injury while midfield stalwart Darlington Nagbe was a shock exclusion from the lineup with his own injury. The Black & Gold made do by shifting Pedro Santos into the No. 10 role and gave Fatai Alashe his second straight start beside Artur.

The Fires goal begins in the midfield with Alvaro Medran picking up the ball and quickly playing a pass over to Gaston Gimenez.

With Alashe recovering and Santos shifting over to provide pressure, Gimenez pings the ball back out in front of Medran.

Medran has time and space in front of him and heads toward the Crews half of the field. On the other side of the field, Harrison Afful spots the Chicago counter attack and sprints back toward his defensive end.

Medran is able to continue forward and the counter attack is on for the Fire. At this point, Columbus has two defenders providing immediate cover in Milton Valenzuela and Artur, two center backs further back who are split by Chicago striker Robert Beric, and Afful attempting to close down on the free-running Mihailovic. Both of the Black & Golds wingers have pushed up the field, leaving Medran free to carry the ball forward.

Medran crosses midfield without any resistance. Artur shifts away from Ignacio Aliseda in order to provide some pressure on Medran, leaving the Fire midfielder with five options. He can play a quick diagonal pass to Aliseda, play a long ball over the top to Mihailovic, make a through pass to Beric, carry the ball forward or play a diagonal pass in front of Fabian Herbers.

Medran spots Beric running between the Black & Gold center backs and hits a long through ball into space for his striker to run onto. As Medran hits that pass, Josh Williams shifts away from Beric in an attempt to intercept the pass. If he does pick up the ball, this will allow the Crew to clear out of danger. If he is unable to intercept the pass, it will force captain Jonathan Mensah into the difficult position of defending both Berics run as well as any additional runs made to the back post.

On the far side of the field, Mihailovic and Afful are engaged in a foot race down the attacking left flank.

Williams is unable to intercept the pass, leaving Mensah alone to cover both Beric, who is running onto the long through ball, and Mihailovic running back post. Afful is scrambling to recover on the young attacker but is outpaced.

Beric, unpressured, catches up to the ball in the Columbus goal box and immediately has three options before making his first to a quick shot on goal, a cross toward Mihailovic or carry the ball closer to the goal.

Mensah has put himself into the best position he can while knowing that Mihailovic is running free toward the goal. In this no mans land, Mensah will attempt to get in front of a cross or provide further pressure should Beric decide to take an additional touch on the ball.

Beric reaches the ball and hits a first touch cross toward Mihailovic.

On first glance, it appeared that Mihailovic might have been offside, but from the side angle you can see that he is just a few steps behind Mensah as the ball is crossed toward the back post.

Mensah slides toward the ball but is just unable to get a touch as the ball slides past the captain toward the back post.

Afful is unable to catch up to Mihailovic who will have an uncontested chance on the ball.

Eloy Room shifts toward Mihailovic who hits a first-touch shot toward the goal.

Room is unable to get in front of the ball as it travels past him . . .

. . . into the back of the net.

Findings:

The rest is here:
Anatomy of a Goal: Mihailovic gives Fire an early lead vs. the Crew - Massive Report

Forget the GreeksIs This the World’s Oldest Anatomical Text? – Daily Beast

If you were to take a class on anatomy in med school you would probably be told that the history of anatomy really begins in the Renaissance, when doctors and other luminaries like Leonardo da Vinci first started dissecting human bodies and documenting their findings. You might also learn that prior to this point, doctors worked with the anatomical theories of the ancient Greeks and Romans, whose knowledge was gleaned mostly from the bodies of animals and external observation. The ancient Egyptians, who are well known for cutting up dead bodies, might get a look in, but that would likely be it.

But, now, a new study claims that an ancient manuscript unearthed in a tomb in Southern China may well be the worlds oldest anatomical atlas. The article not only promises to revolutionize our understanding of the history of medicine, it also sheds light on the history and scientific foundations of acupuncture.

In an article inThe Anatomical Record, Vivien Shaw and Isabelle Winder of Bangor University, UK, and Rui Diogo of Howard University published their findings about the Mawangdui manuscripts, a collection of philosophical and medical texts from Changsha in the Hunan province of South Central China. The texts are written on silk and were placed in the tomb of Chancellor Li Cang and his family before it was sealed in 168 BCE. They were rediscovered in the 1970s, but the previously unknown medical texts were somewhat overshadowed by the presence of other important discoveries, like the oldest copy of the I Ching. Because of this, Shaw, Winder, and Diogo are the first to treat these medical texts as evidence of ancient anatomy.

The Mawangduitexts, the authors argue, were written in the second-third century BCE and are roughly contemporaneous with now-lost Greek dissection-based anatomical texts. Of course, the approach taken in these Chinese texts is very different than the one we see in their Greek counterparts. Vivien Shaw said, they looked at the body from the viewpoint of traditional Chinese Medicine, which is based on the philosophical concept of complementary opposites of yin and yang, familiar to those in the west who follow eastern spiritualism.

The Mawangduitexts organize the body into eleven pathways, each of which has particular kinds of disease associated with it. Some of these, Isabel Winder said, map onto later acupuncture meridians, even though acupuncture and acupuncture points are nowhere mentioned. Historians had some evidence for the acupuncture meridians from other ancient Chinese texts, but those texts date to the third century CE and are, thus, roughly four hundred years younger than the ones from Mawangdui.

Their findings, said Shaw, not only re-write a key part of Chinese history and affirm that the Han dynasty was a period of widespread intellectual growth, they also provide medical foundations for acupuncture and change our understanding of how it originally worked.

We believe, she said, that our interpretation of the text challenges the widespread belief that there is no scientific foundation for the anatomy of acupuncture, by showing that the earliest physicians writing about meridians were in fact describing the physical body. Modern acupuncture, Shaw added, is grounded in the belief that it is the function of the meridian points thats important. Originally, however, it seems that Chinese anatomists were interested in mapping the structure of the body. In other words, and regardless of whether or not we think these descriptions of the body are accurate, they are scientific. This means that acupuncture, which is often dismissed as more spiritual than scientific, is grounded in a carefully worked out ancient map of the body that was based on scientific observation.

The reason that the Mawangdui texts have been overlooked as an anatomical resource is because they date from a period when the principles of Confucianism were very much in vogue. Han-era China was governed by Confucian law, which maintained stability and structure through the maintenance of a rigid social structure. One element of this social hierarchy was what is called filial piety, in which children must respect and honor their parents. Venerating ones ancestors did not include cutting up your dead parents. As Isabel Winder, one of the authors of the article, said Confucian cultural practices shunned dissection. However, [the evidence leads us to conclude] that dissection was involved and that the authors [of these texts] would have had access to the bodies of criminals.

This brings us to one of the grizzly secrets of the study of anatomy: to be any good at it you have to be examining actual human bodies. At the time, this was not just a Chinese practice. Herophilus of Chalcedon and his younger contemporary Erasistratus of Ceos, Greek-speaking doctors and medical authors working in Alexandria, Egypt in the first half of the third century BCE, were also dissecting cadavers on a routine basis. As in China (and, later, in 16th 19th century Britain), the bodies used for these experiments were those of criminals. Shortly after Herophilus and Erasistratus died, however, dissection fell into disuse. Though there were some rogue doctors who seem to have been dissecting bodies on the sly it wasnt until the 14th century, when the Italian Mondino de Luzzi publicly performed the first sanctioned dissection in a millennium, that it would begin again in earnest.

While dissection vastly improved medical sciences understanding of the workings of the human body, this doesnt mean that those performing these experiments always accurately described what was in front of them. Leonardo da Vincis scientific drawings of the human body are widely admired for their accuracy, but he sometimes followed tradition rather than the evidence, depicting, as Roy Porter has written in his book The Greatest Benefit to Mankind, a five lobed liver. The human liver only has four lobes; the five-lobe theory was based on the dissection of dogs and pigs and goes back to Hippocrates. We should not assume, therefore, that dissection always deepens and improves medical understanding. It took two hundred years and the creative vision of 16th century anatomist Andreas Vesalius for many ancient medical theories to be questioned and revised.

In between the 3rd century BCE and the rediscovery of dissection in the 14th, European doctors were reliant on the works of famous Greek-speaking doctors Aristotle and Galen, who had only dissected animals. Galen had experience treating gladiators and would have seen the kinds of wounds that would have afforded the opportunity peek inside the body, but there was nothing exhaustive about his exploration of the human body. As a result, all kinds of errorsthe five-lobed liver sketched by Da Vinci, for examplecrept into Western medicine. So, if youre thinking that Chinese medicine sounds unscientific and esoteric, bear in mind that for this 1200-year period of European history you may as well have been seeing a vet.

One of the major contributions of this study is the way that it challenges Eurocentric histories of science and medicine. Rui Diogo, whose lab helped perform the research, told The Daily Beast, that too often textbooks and scientific publications rehearse narratives in which white Europeans (from the Greeks and Romans onwards) make the big discoveries and non-European cultures contribute nothing more than translations of Greek texts or esoteric unscientific knowledge. Discoveries like this one show both that there was a vibrant scientific culture in places like India, China, and Persia and also that medical schemes often dismissed as esoteric have real scientific foundations.

Read the original:
Forget the GreeksIs This the World's Oldest Anatomical Text? - Daily Beast

Reconstructing Kimberella The Disputed Anatomy in Detail – Discovery Institute

Photo: Kimberella, by the paleobear from Lontananza, Loreto, Peru / CC BY (https://creativecommons.org/licenses/by/2.0).

Editors note: We are delighted to present a series of posts by paleontologist Gnter Bechly on the Ediacaran organismKimberella. If identified as an animal, it would predate the Cambrian explosion of bilaterian animal phyla as a kind of advance guard.The question is of interest for debates about evolution and arguments about intelligent design raised by Stephen Meyer, among others.Find the full series aboutKimberellahere.

In my opinion the third phase reconstruction ofKimberella, byFedonkin (2007b)and described here yesterday, is better supported by the fossil evidence than the new reconstruction ofIvantsov (2009). Not only is Fedonkin more likely correct concerning the head and feeding apparatus with a medium sized proboscis armed with two teeth. He also successfully addressed all the arguments that Ivantsov listed against a single shell. You can find a pretty decent life-reconstruction and animation ofKimberellaat thePalaeoZoowebsite.

With their revolutionary new interpretation ofKimberellaas a benthic bilaterian animal,Fedonkin & Waggoner (1997)first recognized the presence of a creeping ventral locomotory organ (foot), which was accepted by most subsequent authors (a notable exception wasDzik 2003).Fedonkin et al. (2007b)explicitly identified this structure as a true foot, possibly comparable in structure with that of monoplacophorans.Fedonkin et al. (2007b)also described fine transverse wrinkles on the sole of the foot, which they interpreted as transverse ventral musculature (compareSeilacher et al. 2003who likewise described the flat foot with a ring of segmental muscles, whose contraction upon death produced equidistant wrinkles). They suggested backward movement by peristaltic waves and also suggested that the foot was contracted in some specimens in a manner similar to modern limpets.

It was againFedonkin et al. (2007b)who first explicitly suggested the presence of a mantle and mantle cavity inKimberella.Ivantsov (2009)agreed, but consistently used the term mantle with quotation marks because he doubted a homology with the molluscanmantleor pallium, which is the technical term for their protruding dorsal body wall.

More recent authors all affirmed the presence of a mantle: For example,Gehling et al. (2014: fig. 9)mentioned that the serrate zone has been interpreted as a corrugated mantle frill overlying a wider central muscular foot.

According toWanninger & Wollensen (2019)Kimberellahas an elongated, slender foot surrounded by a mantle that is separated from the former by a circumpedal mantle cavity (also seeVinther 2015).

In the most recent textbook on invertebrate phylogeny, byGiribet & Edgecombe (2020), the authors say aboutKimberellas anatomy that the softer ventral side has been described as a sole and compared to a molluscan foot. The body is certainly zoned laterally, this zonation viewed as representing the foot and mantle separated by a groove in the mollusc model.

It is safe to say that since the redescription ofKimberellaas a benthic bilaterian animal, the functional interpretation of foot and mantle has met with a broad consensus among the specialists and represents one of the less controversial issues of its anatomy. However, what remains highly disputed is the question of the homology of these structures with the foot and mantle in modern mollusks.

According to esteemed Russian expert Mikhail Fedonkin,Kimberellahad a non-mineralized univalved shell with an elongated oval, shield-like outline (Fedonkin & Waggoner 1997, Fedonkin 2001,2003,Fedonkin et al. 2007b). Likewise, Fedonkin (1998, 2001) andWaggoner (1998)said thatKimberellabore a highly compaction-resistant structure that we interpret as a stiff but un-mineralized shell, andFedonkin (2003)specified that the elongated and high dorsal shell [was] made of flexible and rigid organic material.Fedonkin et al. (2007b)found that the outer surface of the dorsal side of the smaller specimens is covered with numerous round protuberances, uniformly spaced over the major part of the shell, which they interpreted as outgrowths, or bases of mineral spines, or as separate initial nodules of shell formation. This latter hypothesis might explain why these structures are not visible in the larger adult specimens. Finally,Fedonkin et al. (2007b)also recognized that small specimens often are strongly elongated, and suggested that these individuals represent a phase when the formation of the shell had not yet begun or was just incipient. They explained that the taphonomic varieties of the shell imprints clearly demonstrate that the shell was stiff, but thin and flexible, particularly in juveniles, which explains why stretched and laterally bent specimens are generally small.

Based on further new material, the other Russian expert Andrey Ivantsov (2009,2010b) suggested a new reconstruction with hard sclerites, probably of aragonite, rather than a complete consolidated shell. Because of the very different contracted and stretched morphs ofKimberella,Ivantsov (2009: pls I-II,2010b: pl. 1,2013) claimed that a rigid shell was not a possibility, and instead suggested a soft-bodied and extremely flexible organism with multiple dorsal mineralized sclerites. He said that many characters of the imprints contradict the hypothesis of a single shell, including the many stretched and strongly bent specimens. This is somewhat strange, because we have just seen thatFedonkin et al. (2007b)had already explained this phenomenon ontogenetically. Ivantsov also claimed that the absence of any growth lines is very much unlike molluscan shells, even thoughFedonkin et al. (2007b)suggested that the absence of any growth zonation in the shell structure suggests that the shell ofKimberellawas the homologue of the periostracum of later Mollusca. Again and again we find opposite conclusions about the same evidence. Finally, Ivantsov mentioned that the head possessed tubercles similar to the body and claimed that all these considerations leave no doubt thatKimberellahad no single dense shell.Ivantsov (2017)suggested that the dorsal body cover was armored with fine sclerites, apparently mineral, but rapidly dissolving after burial, but this taphonomic hypothesis does not explain why the tubercles are only visible in small specimens.

Most later authors followed the single shell interpretation of Fedonkin:Seilacher et al. (2003)mentioned that the dorsal shield, was soft enough to become deformed during burial.Scheltema & Schander (2006)said thatKimberellahad a single, stiff, unmineralized dorsal exoskeleton, which was formed by the mantle cuticle alone, although there may have been a zone of spines beneath the dorsum.Gehling et al. (2014)featured a reconstruction ofKimberellaas a molluscan grade organism with a single shell and said that this reconstruction ofKimberellaincludes an inferred stiff but flexible unmineralized shield that enclosed internal organs.Vinther (2015)remarked thatKimberellahad a dorsal cuticular shield with tubercular nodes.Finally,Wanninger & Wollesen (2019)claimed that the presence of a single non-mineralized shell inKimberellafits well with the hypothetical ground plan of mollusks, since the discovery of the Ordovician fossilCalvapilosa suggested that the two-shelled state of halkieriids and the multi-shelled state of polyplacophoran mollusks represents a derived condition.

Nevertheless, some later authors rather agreed with Ivantsovs new interpretation. For example,Seilacher & Hagadorn (2010)concurred that Kimberellalacked a rigid shell, while being covered by small sclerodermites (Bengtson 2005,Fedonkin et al. 2007b,Ivantsov, 2009). Even more recently,Parkhaev (2017)concluded that in contrast to the first reconstructions , it was shown thatKimberellahad no firm and solid shell, otherwise it would be difficult to explain the observed variability in the shape and proportions of the body in known specimens.

Lay people must be left quite confused by this contr
oversy and might even conclude that paleontology often seems to boil down to an esoteric exercise in reading tea leaves. Unfortunately, sometimes this is the case indeed. Nevertheless, one should always make an inference to the best explanation. In my view the original interpretation of Fedonkin is better supported and he also sufficiently explained the evidence that allegedly supports the alternative interpretation of Ivantsov. Therefore, I conclude thatKimberellamore likelypossessed a non-mineralized integument, a quasi-leathery shell with a characteristic ornamentation, which was flexible in juvenile specimens but rather stiff in adult ones. But this is just my humble opinion and it is quite clear that this issue is controversial and far from settled.

Fedonkin & Waggoner (1997)speculated that the crenellated structures may have had a respiratory function and even mentioned the possibility that the crenellations may have hosted microbial symbionts.Fedonkin et al. (2007b)said that there is no evidence of gills inKimberella, while the large surface of the multifolded crenulated zone could effectively perform the respiration function. Fedonkin considered these circumpedal respiratorial folds as possible predecessor of the ctenidia (meaning, feathery gills) in aquatic mollusks.

Even though there are indeed no traces of respiratory organs preserved in any of theKimberellafossils, such gills were proposed by Ivantsov (2009,2012) as possibly attached to the scallops along the frilled margin, similar to the serially repeated gills in the Cambrian stem molluskOdontogriphus(Butterfield 2006) and in the circumpedal mantle cavity of primitive living mollusks (Serialia) (Stger et al. 2013). However, Ivantsov also mentioned the alternative possibility that gas exchange occurred across the general body surface. Likewise,Seilacher & Hagadorn (2010)concurred withFedonkin et al. (2007b)andTrusler et al. (2007)that the serial impressions between the foot and the cap probably correspond to flap- or gill-like structures as in modern chitons andNeopilina, and in the CambrianOdontogriphusfrom the Burgess Shale.

However, all this is of course mere speculation in the absence of any conclusive empirical evidence.

Dzik (2003)mentioned that the most prominent aspect ofKimberellafossils is a voluminous depression in their center and proposed that the most likely interpretation is that this was a gut content. This median groove indeed was generally interpreted as simple digestive tract and pharynx (Fedonkin et al. 2007b,Knoll 2011,Vinther 2015). A notable exception wasSeilacher (1999), who thought that the deep cleft along the midline of the foot is clearly a secondary feature related to the burial process and fossilization as ventral death mask (Gehling 1999).Gehling et al. (2014)concurred that the median keel or grove, which is most prominent in smaller specimens, most likely corresponds to a flexible, unmineralized outer integument. Dj-vu, anyone?

Many authors have suggested that the tapered end ofKimberellacorresponded to a kind of proboscis as a feeding apparatus.The alignment between the feeding traces and the tapered open end of the body with the assumed proboscis clearly suggests that this was the anterior (oral) end with the pharynx.

Based on the trace fossil evidence,Ivantsov & Fedonkin (2001b)and Fedonkin (2001,2003) first speculated that the feeding tracks may reflect the work of the proboscis that bears the hook-like organs on its end.Fedonkin (2003)thought that a comparison of the body size ofKimberellaand of the size and pattern of the feeding traces suggests that the hypothetical proboscis could be extended as long as the whole body ofKimberella, and that there were two sharp teeth at its end. Seilacher et al. (2003,2005) also speculated thatKimberellawas a stationary grazer that repeatedly fed with a long proboscis.Dzik (2003)mentioned that in all well preserved specimens ofKimberellathere is a distinctly delimited narrower part of the proposed gut, perhaps representing a muscular oesophagus or even evertible proboscis.

Gehling (1996) andGehling et al. (2005: fig. 12)were the first to clearly document actual fossil evidence for such an extensible head or everted proboscis at the anterior end of theKimberellaanimal. Years later,Gehling et al. (2014: fig. 7)featured more specimens with an everted proboscis, which is never longer than about a fourth of the remaining body length, thus not as long asSeilacher & Hagadorn (2010)and others had speculated.The fact that in most specimens this proboscis is not visible was inferred by these authors to be a result of its retraction within the circumference of the body, but this is completely ad hoc.

This proboscis was described in detail byFedonkin et al. (2007b), who also described a pair of bag-like structures lateral at the base of the proboscis (and thus the assumed pharynx) at the anterior end of the body, which they interpreted as oesophageal pouches or pharyngeal glands (comparable with those found in many extant molluscs) (Fedonkin et al. 2007b: fig. 15; also see: Ivantsov 2009: pl. 1 figs 7-8,Vinther et al. 2012,Vinther 2015: fig. 3E).Fedonkin suggested that the feeding traces were left by a solitary conjugate pair of teeth located at the end of a long proboscis that stretched far forward beyond the main body (Ivantsov & Fedonkin 2001b,Fedonkin 2003,Fedonkin & Vickers-Rich 2007,Fedonkin et al. 2007b).

In the paper byFedonkin et al. (2007b)an alternative interpretation by co-author Ivantsov is mentioned: instead of an elongate proboscis, there could have been a rather wide feeding organ, which could spread like a fan. Equipped with numerous teeth this organ scratched a large surface area of the sea floor in one simultaneous sweep. However, Fedonkin et al. concluded that mechanical constraints and the absence of morphological evidence do not allow us to accept this model.Ivantsov (2009)likewise claimed that the very flexible organism, which must have lacked a hard shell, made a long proboscis unnecessary. Indeed, no such long proboscis is visible in any of the fossil specimens.His alternative view was further elaborated by Ivantsov (2010b,2012,2013), who claimed that: The mobile animal with a long, flexible proboscis freely bending in all directions should leave more chaotic traces. This implies that the animal got deeper into the mat using a larger structure with several teeth and limited ability for lateral bending, rather than separate teeth located at the end of the flexible proboscis. Such a structure was most likely represented by the entire anterior part of theKimberellabody together with a large head, which was able to extend and widen (Ivantsov,2009,2010,2011). He suggested that the tooth battery was folded on both sides of the pharynx, and that the expandable spatulate head was at least partly retracted in the fossil specimens. Nevertheless,Ivantsov (2013)admitted that his hypothesis could not explain the distinct pairs of ridges in the trace fossils. In his most recent paper,Ivantsov et al. (2019)apparently addressed this problem and now says that the head ofKimberellawas wide and spatulate in a straightened state, and it bore two or more sclerotic teeth.

Other authors have added various further speculations about this feeding apparatus.

Trusler et al. (2007)warned that instead of an elongate proboscis bearing only a pair of resistant structures,Kimberellamay have possessed a much more complex radular morphology, again analogous to that present in monoplacophorans , which did not require a lengthy extension of the feeding organ. In fact, it may well be that the feeding structure was entirely beneath the organism or only slightly extended when it farmed the microbial mat and its contents, and only protruded beyond the main body in death when compressed. However, this view is contradicted by the fact that the only known resting trace does not overlap with the surrounding feeding traces (see below).

Seilacher & Hagadorn (2010)suggested that hydrostatics and muscles likely operated this extendable and flexible proboscis. H
ypothetically, such a proboscis could have handed food particles to a proximally situated mouth, in the mode of an elephants trunk or the antennae of the amphipodCorophium. Alternatively, and more likely, the mouth was at the very tip of the proboscis, with radular teeth delivering their crop directly into the esophagus.

Grazhdankin (2014)added that the retractable anterior end ofKimberella quadratapossessed a peculiar sagittate structure , which, at least superficially, is remarkably similar to individual representatives of the generaParvancorinaandTemnoxa. which are both problematic Ediacaran organisms of uncertain affinity.

Budd & Jensen (2017)correctly remarked that the production of the fan-shaped scratch marks would have required a very long introvert in order to create the observed pattern, and this has not been seen. Therefore, they concluded that considerable uncertainty remains as to how the scratches were formed and by what type of device. I fear this is a fair characterization.

For those scientists, who believe that the teeth ofKimberellawere really homologous to a molluscan radula (e.g.,Seilacher 1999,Caron et al. 2006,Seilacher & Hagadorn 2010,Vinther et al. 2012,Stger et al. 2013), there is another fundamental problem: the apparatus is postulated at the end of an everted tubular proboscis (Gehling et al. 2005), which is never the case in mollusks and would rather resemble the introvert in scalidophoran nemathelminths (Cephalorhyncha) (Budd & Jensen 2017). However, the worm-like body plan of such nemathelminths like Priapulida does not agree with the morphology seen inKimberella(Gehling et al. 2014).

Finally, another severe problem remains: even though many of the fossil specimens from the White Sea region are quite well-preserved, there is not a single one that clearly shows a toothed radula-like organ. However, in two specimens (figured byFedonkin et al. 2007b: fig. 15j,Ivantsov 2009: figs 2c and pl. 1 fig. 6,2010b: pl. 1 figs 4-5,2013: pl. II figs 1-2, and2017: fig. 2-2) there is a series of deep grooves near the end of the short proboscis, which may or may not correspond to teeth. Actually, in my view their structure does not fit well with the bifid pattern of theKimberichnustraces, andGehling et al. (2014)had similar reservations.Budd & Jensen (2017)mentioned that these grooves look very similar to structures at the posterior end of the body, which were interpreted by Ivantsov as evidence for longitudinal muscles. Ivantsov explained the general absence of imprints of teeth as an artifact of preservation, based on their covering by the muscular part of the head and the dense mantle, but of course this is just another ad hoc hypothesis.

Thus, as in most other structures ofKimberellathe interpretation of the feeding apparatus turns out to be very controversial: Was there a long or a short proboscis, or no proboscis at all but a broad expandable head? Was there a pair of large teeth, or two sets of small teeth, or no teeth at all? Were the paired bag-like structure muscles, or glands, or something else entirely? Fossils often leave much room for very different interpretations of relatively poor evidence, so that paleontologists always should be very careful not to stack elaborate hypotheses like a house of cards, which of course happens anyway and even quite often so.

Next, Kimberella Controversial Scratch Marks.

Read the original here:
Reconstructing Kimberella The Disputed Anatomy in Detail - Discovery Institute

Career anatomy: The resum of Wall Streets first woman CEO, Jane Fraser – Boss Betty

Wall Streets big bank big-wigs will soon have a new executive among them and, unlike the rest of them, she is, well, a she. (Yes, that is lamentably still very remarkable in 2020.) Citigroups Jane Fraser, who has been with the bank for 16 years, will be promoted to CEO in February following the retirement of Michael Corbat.

Fraser will be the first woman to lead a major U.S. bank and will be joining an ultra-rarified rank of executives that includes JPMorgan Chases Jamie Dimon, Goldman Sachs David Solomon, Wells Fargos Charles Scharf and Bank of Americas Brian Moynihan, among others. She will be the only female CEO among the 10 largest U.S. banks. Sachs Solomon welcomed her to the club, posting his congratulations on LinkedIn and calling her a pioneer. Bank of Americas Cathy Bessant, who was rumored to be in the running for the CEO spot at Wells Fargo last year (the post went to Scharf), tweeted that Frasers appointment was Great news for the company and for women everywhere!

Fraser, who was born in Scotland, currently serves as Citis president and CEO of Global Consumer Banking.

So, how did this glass-ceiling smasher get to the very highest echelon of finance? We figured that for all of us aspiring ceiling-breakers it would be helpful to trace the path of her career, so we took a stab at recreating Frasers resum using her LinkedIn profile, additional research and perhaps a wee bit of creative license (with the design, never the facts, and no, we wont be giving up our day jobs for resume design any time soon).

Whats not noted among her staggering accomplishments is the constant challenge of being a working mom: Being a mother of young children and having a career is the toughest thing I have ever had to do, she said in an internal interview at McKinsey, according to Axios.

Alright, without further ado, Boss Bettys re-creation of the resum of Wall Streets first female big bank CEO, Jane Fraser:

The rest is here:
Career anatomy: The resum of Wall Streets first woman CEO, Jane Fraser - Boss Betty

Anatomical characterization of the inguinal lymph nodes using microcomputed tomography to inform radical inguinal lymph node dissections in penile…

Radical inguinal lymph node dissections (rILND) for penile cancer risk significant postoperative lymphocele and lymphedema. However, reducing the risk of lymphatic complications is limited by our understanding of lymphatic anatomy. Therefore, this study aims to elucidate the lymphatic anatomy within the current surgical borders of a rILND.

To visualize the position of the lymph nodes, tissue packets excised from the inguinal region of five fresh, male cadavers were imaged using microcomputed tomography (CT). To standardize the position, rotation and size between specimens, each lymph node packet was aligned using a Generalized Procrustes analysis.

There was a median of 13.5 lymph nodes (range=8-18) per packet, with the majority (99%) clustered within a 6cm radius of the saphenofemoral junction; a region 39%-41% smaller than current surgical borders. No difference existed between the number of nodes between sides, or distribution around the saphenofemoral junction.

This study provides the first 3D, in situ, standardized characterization of lymph node anatomy in the inguinal region using CT. By using knowledge of the normal lymphatic anatomy, this study can help inform the reduction in borders of rILND to limit disruption and ensure a complete lymphadenectomy.

Journal of surgical oncology. 2020 Sep 10 [Epub ahead of print]

Kait Marshall, Shiva M Nair, Katherine E Willmore, Tyler S Beveridge, Nicholas E Power

Department of Anatomy & Cell Biology, Schulich School of Medicine & Dentistry, Western University, London, Ontorio, Canada., Department of Surgery, Urology Division, Schulich School of Medicine & Dentistry, Western University, London, Ontorio, Canada.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/32914446

Read more here:
Anatomical characterization of the inguinal lymph nodes using microcomputed tomography to inform radical inguinal lymph node dissections in penile...

Anatomy of a Crisis: Why the China-India Border Standoff Is Cause for Concern – The National Interest

In June 2020, reports of a serious military clash involving India and China, one that led to the death of at least twenty Indian soldiers came as a shock to the international community. While journalists raised concerns over incursions from the Chinese side into the unmarked border in the Ladakh region of Jammu and Kashmir (the Line of Actual Control, or LAC), New Delhi and Beijing engaged in efforts to de-escalate the tensions. The incident acquired a more sinister tone as it was the most significant and overt India-China conflict since 1962. A lack of clarity on operational realities from the ground gave further fuel to a discourse driven by nationalism in both nations, amidst a global pandemic and new regional economic realities. The recent clashes, however, need to be considered from a regional as well as a global perspective, with significant dynamics also driven by India and Chinas respective political situations.

The recent escalation has brought with it various levels of enquiry regarding power asymmetries between India and China, the continuing relevance of historical border conflicts as well as the lack of attention to China policy in an Indian foreign policy discourse that has remained predominantly Pakistan-centric. This despite the shock of the 1962 war with China, which came as a surprise to an India that was driven by an emphasis on the spirit of Prime Minister Jawaharlal Nehrus Panchsheel, doctrine made famous for its much-applauded slogan, Hindi Chini Bhai Bhai (Indians and Chinese are brothers).

There has been however a gradual recognition of the looming Chinese threat in India. It was also one of the driving forces for Indias decision to develop and test nuclear weapons, even though the stated connection with Pakistan became a preferred media story. India has been heavily invested in building its military capabilities over the years with reports ranking India at the number two position for weapon imports at 9.2 percent of the worlds total between 2015 and 2019.

Until the border incident in June 2020, the India-China conflict has remained subtle if not dormant. The first Sino-Indian War of 1962 was triggered by a series of events including border skirmishes and Indian support to the Tibetan cause and political refuge to the Dalai Lama, issues that continue to remain relevant, much to Chinese displeasure. There has been however an attempt at positive engagement. The two sides met during 1993 and 1996 and reached the two Sino-Indian Peace and Tranquillity Accords. Key features of these agreements include soldiers not allowed to carry weapons along the LAC and joint military exercises.

Despite India and Chinas partnership in the BRICS and other regional forums representing the interests of the global South, economic and geopolitical competition between the two powers has also been on the rise. Chinas ambitious Belt and Road Initiative (BRI) and its continued expansion into South Asia has troubled India that has traditionally considered South Asia as its own sphere of influence. India views Chinas ports in the Indian Ocean through the string of pearls lens harming its strategic interests and security. There are already visible signs of Sino-Indian competition for influence in smaller South Asian countries including Bangladesh, Nepal, Maldives, and Sri Lanka.

To counter Chinas growing influence, India has joined the United States, Australia, and Japan through a strategic partnership under the Quadrilateral Security Dialogue (Quad). Indias recent engagement with the United States as well as global anger towards Chinas role in the coronavirus pandemic has also influenced recent tensions. China and India were also involved in a confrontation in Doklam in 2017 but the dispute did not escalate. Domestically, however, both nationalist governments claimed credit and victory. For China, engaging India aggressively is also an aspect of President Xi Jinpings domestic power play. The Indian government, under the nationalist Prime Minister Narendra Modi, is also significantly driven by a muscular foreign and domestic policy. The revocation of the controversial Article 370 on Jammu and Kashmir and the creation of an independent union territory of Ladakh (that neighbors China) has also been argued to have triggered Chinas reaction and the use of aggressive military tactics. In a disturbing development, Indian soldiers were killed by using nail-studded rods in the confrontation in June 2020.

Despite a slow starting reaction, driven by Modis overtures towards China and a possible intelligence failure, India has now stepped up diplomatic, political and military pressure on China. Aiming to hurt Chinas economic might, the Indian state has banned several Chinese apps. Diplomatic and political pressure on China through the US and the Quad nations has also increased in the past few months. Even though Chinese and Indian negotiators work on an agreement on the border clashes, there are reports that the Indian army launched a counter operation against attempts by Chinas Peoples Liberation Army to cross into the Indian side of the LAC, south of the Pangong Tso lake in Ladakh and to occupy a mountain called Helmet Top. Amidst rising mistrust and pressure on the Indian government to retaliate, there are chances of further escalation of tensions along the fraught border regions.

Considering the broader context of Sino-Indian relations, it is highly likely that the tensions will grow amidst regional and global realignments. India is increasingly troubled not just by Chinas increasing influence in its neighborhood but also by its deteriorating relations with some of its erstwhile regional partners, such as Bangladesh and Nepal. By virtue of the continued economic growth, China has gradually also entered the era of Wolf Warrior diplomacy to exert its influence and the BRI is part and parcel of this approach. As India continues to oppose the BRI and Chinas rise through its alliances, the conflict with China is likely to increase further.

Dr. Stuti Bhatnagar is an adjunct fellow associated with the School of Social Sciences at the University of Adelaide and the University of New South Wales, Australia.

Dr. Zahid Shahab Ahmed is a Research Fellow at the Alfred Deakin Institute for Citizenship and Globalization, Deakin University, Australia.

Image: Reuters.

More:
Anatomy of a Crisis: Why the China-India Border Standoff Is Cause for Concern - The National Interest